about
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerApplications of next-generation sequencing to blood and marrow transplantationEvaluation of published single nucleotide polymorphisms associated with acute GVHDHLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathwayDetermination of intronic sequences adjacent to an exon using polymerase chain reaction and genomic DNA library constructed by TA cloning.C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host diseaseTreatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen.Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones.Application of T cell immunotherapy for human viral and malignant diseases.Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens.An antigen produced by splicing of noncontiguous peptides in the reverse order.T-cell therapy of leukemia.Minor histocompatibility antigens--targets of graft versus leukemia responses.Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient miceThe graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cellsEpigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancerCD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft modelAdoptive transfer of allogeneic antigen-specific T cells.A human minor histocompatibility antigen resulting from differential expression due to a gene deletionHigh-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology.Toward eliminating HLA class I expression to generate universal cells from allogeneic donorsEvaluation of NIH consensus criteria for classification of late acute and chronic GVHD.Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.Graft versus leukemia reactivity after allogeneic stem cell transplantation.Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.Genetic modification of T-cell clones for therapy of human viral and malignant diseases.Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling.Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.A multi-center Phase 1 trial of ipilimumab in myelodysplastic syndrome patients following hypomethylating agent failure.Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.
P50
Q24685666-166EA0C2-A604-4AEE-9FC9-EC259BFA5E27Q26740288-A67CA631-70B7-4EB3-AEE7-F6A05C4DE43CQ26852890-E67AE1E9-4785-4FEC-A2A9-FB9BD3482866Q27026616-5984B4BD-DCBE-41E2-8000-87983F1DFEA1Q28294499-886D8A86-A479-43F0-8A9D-5D8B289BCFC1Q30650248-C2D6BE46-F63B-4760-A4E0-4CE9A16C5DA4Q33359498-AECC15A7-4C58-44C8-8702-F798EE892F5AQ33583414-0EDA1285-F3E9-4099-992F-5C4CCB98D189Q33608255-E8B285EE-894D-42A3-B078-0DB71172B4FBQ33691970-5454A945-D98B-497C-8305-3068625D31BAQ33890464-CB1CE0B2-541E-40B1-988C-90FBF96DB791Q33955090-E37F41D4-C0C1-4D4F-BC27-274F4C72D720Q34003692-C047C569-2A45-4D03-907A-DCFD8F59EEB5Q34140624-F30AE809-CC8E-45FD-9734-0A68318414A2Q34564542-33B277AC-6582-486A-BCAE-3ED3EFCF112DQ34608658-8544EB16-1A44-4B35-9FF5-2C86C584030DQ34996292-39831DB4-9566-4BAD-A064-147BBF3163A2Q35053317-62735416-932A-44B5-A586-9C3F9DEB5A41Q35158955-485153BD-054E-4B04-82F4-3928F1EB1284Q35224947-6D944E72-F124-4D89-A4A2-DB1D82BEFCA7Q35558987-169119A3-A22B-4034-8412-D06636914094Q35782660-70C16FC4-A025-40B0-BC9E-4E2D66FF67F1Q36177214-454C247A-E122-49FD-A267-51FF5C1EA166Q36363385-F197C912-3284-4E2D-82EC-BDBF2F8F5485Q36370375-B6309793-27E1-4E77-93A1-D60608F7C050Q36983736-B6B16E14-FB02-4DF4-B2AA-3D95FEC3CD47Q37113074-DE6A5488-275F-4AA7-BC56-19B4774ABD10Q37268970-E02B4AF1-A039-4FDD-A269-EF63B1A4C5EEQ37291529-C7A98DB4-15B4-4234-867B-EC373A2B85ACQ37824992-C5A36AF4-D590-4091-B183-743D84BF319EQ38861782-20B34D7C-7909-49B2-BA9E-647B8C21E9ECQ43696495-5138D648-E783-4032-B997-4EEE78024C6AQ44083618-F719A5DF-CDDC-4948-9716-C03FCB63A1A0Q45178434-734327D3-61BF-490E-9ADD-D9B1494979EDQ47385454-C6EFB9D8-3EAF-4F3C-99BE-980EF1CFC7A7Q47631013-3A02C658-EA2C-4163-B7F3-9533557E8B6BQ48208819-EEA85FB9-C76D-452C-855E-4AD9F3DA4879Q50223662-CCC3869B-ABFC-46E2-A4EC-B12D72132B91Q52714959-17EE9D44-E307-478B-AAD6-E53F70257E2CQ53528762-3A2484C0-F1C8-4757-A923-6A5FF4E3067A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Edus H Warren
@ast
Edus H Warren
@en
Edus H Warren
@es
Edus H Warren
@nl
Edus H Warren
@sl
type
label
Edus H Warren
@ast
Edus H Warren
@en
Edus H Warren
@es
Edus H Warren
@nl
Edus H Warren
@sl
prefLabel
Edus H Warren
@ast
Edus H Warren
@en
Edus H Warren
@es
Edus H Warren
@nl
Edus H Warren
@sl
P106
P21
P31
P496
0000-0002-9570-2755